The commercial momentum is soaring, with total revenue increasing by an impressive 84% year-on-year. HENLIUS (02696) has shown outstanding performance in the first three quarters.

On November 15, HENLIUS (02696) released its performance for the first three quarters of 2023. As of September 30, 2023, the company achieved operating income of approximately RMB 3.9278 billion, a year-on-year increase of approximately 84.0%. The company's profit in the first three quarters of 2023 reached RMB 407.8 million, mainly derived from the continuous increase in the company's excellent commercialization efforts and efficient implementation. HANSIQ (toripalimab) and HANSZHUANG (sulituzumab) achieved sales revenue of RMB 2.0145 billion and RMB 865.4 million respectively in the first three quarters of 2023. In the third quarter of 2023, HENLIUS maintained a high growth momentum, significantly increasing the sales volume of multiple commercialized products and achieving milestone progress worldwide, with a total sales revenue of RMB 1.2256 billion. Among them, the company's core tumor products HANSIQ, HANSZHUANG, and HANBEITAI (bevacizumab) achieved sales revenue of approximately RMB 737.8 million, RMB 309.1 million, and RMB 36.4 million respectively. In addition, based on agreements with partners, the company obtained approximately RMB 131 million and RMB 11.3 million in sales profit sharing for HANLIKANG (rituximab) and HANDAYUAN (adalimumab) respectively. In 2023, HENLIUS made significant progress in overseas expansion and opened up new growth opportunities internationally. Based on contractual agreements, the company obtained approximately RMB 546.7 million in authorized licensing and research and development service income in the first three quarters of 2023, a year-on-year increase of 232.1%. During the reporting period, the company further collaborated with partners to expand the global commercialization blueprint for HANSIQ. In September 2023, the company once again partnered with KGbio, a partner in the ASEAN region, to reach an agreement on the exclusive development and commercialization rights of HANSIQ in 12 countries in the Middle East and North Africa. In October 2023, the company expanded its collaboration with Intas and authorized its exclusive development and commercialization rights for HANSIQ in Europe and India, with potential total revenue expected to reach 185 million euros. HENLIUS stated that by focusing on unmet clinical needs, the company will continue to solidify the advantages of its integrated research, production, and sales platform, steadily promote innovative layout and overseas expansion, and jointly create an international biopharmaceutical platform with higher value to benefit more patients worldwide.